860003-88-9

Usage

Uses

Used in Pharmaceutical Research:
8-BROMO-2,3-DIHYDRO-1,4-BENZODIOXINE-6-CARBALDEHYDE is used as a key intermediate in the synthesis of various pharmaceuticals for its unique reactivity and pharmacological properties. Its bromine atom and benzodioxine ring structure contribute to the development of new drugs with potential therapeutic applications.
Used in Organic Synthesis:
In the field of organic synthesis, 8-BROMO-2,3-DIHYDRO-1,4-BENZODIOXINE-6-CARBALDEHYDE serves as a versatile building block for the creation of complex organic molecules. Its aldehyde group allows for a variety of chemical reactions, facilitating the formation of new compounds with diverse applications.
Used in Chemical Process Development:
8-BROMO-2,3-DIHYDRO-1,4-BENZODIOXINE-6-CARBALDEHYDE is employed as a reactant in the development of novel chemical processes. Its unique reactivity and properties can be harnessed to improve existing processes or to create new ones, potentially leading to more efficient and sustainable chemical production methods.

InChI:InChI=1/C9H7BrO3/c10-7-3-6(5-11)4-8-9(7)13-2-1-12-8/h3-5H,1-2H2

Upstream product

• 16414-34-9 3-bromo-4,5-dihydroxybenzaldehyde 
• 106-93-4 ethylene dibromide 
• 121-33-5 vanillin 
• 2973-76-4 5-bromo-4-hydroxy-3-methoxybenzaldehyde 

Downstream Products

• 868707-84-0 8-methyl-2,3-dihydrobenzo[b][1,4]dioxine-6-carbaldehyde 

Relevant academic research and scientific papers

TRYCLIC NITROGEN CONTAINING COMPOUNDS AND THEIR USE AS ANTIBACTERIALS

Tricyclic nitrogen containing compounds of formula (I) and their use as antibacterials.

Methods of using diaminopyrimidine P2X3 and P2X2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases

Methods for treating respiratory and gastrointestinal diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein D, X, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.

ANTIBACTERIAL AGENTS

Naphthalene, quinoline, quinoxaline and naphthyridine derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.

ANTIBACTERIAL AGENTS

Naphthalene, quinoline, quinoxaline and naphthyridine derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.

Heteroarylisopropylamines as MAO inhibitors

The in vitro monoamine oxidase inhibitory (MAOI) activities of 11 heteroarylisopropylamines vis-a-vis MAO-A and MAO-B were described and interpreted in terms of possible interactions with the enzyme active site. Molecular dynamics simulations allowed a comparison between the most active MAO-A inhibitor of the series, the 1-(2-benzofuryl)-2-aminopropane, and the specific, analogous MAO-A substrate serotonin.

Diaminopyrimidines as P2X3 and P2X2/3 antagonists

Compounds and methods for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein D, X, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.